From what 0 stock analysts predict, the share price for Inari Medical Inc (NARI) might increase by 29.01% in the next year. This is based on a 12-month average estimation for NARI. Price targets go from $48 to $86. The majority of stock analysts believe NARI is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedNARI 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Inari Medical Inc to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on NARI. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of NARI.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Mike Matson Needham | Hold | Reiterates | Oct 30, 2024 | |
Mike Matson Needham | Hold | Reiterates | Oct 29, 2024 | |
Richard Newitter Truist Securities | Hold | $50 | Maintains | Oct 29, 2024 |
Adam Maeder Piper Sandler | Neutral | $52 | Maintains | Oct 29, 2024 |
William Plovanic Canaccord Genuity | Buy | $74 | Maintains | Oct 29, 2024 |
David Rescott Baird | Outperform | $67 | Maintains | Oct 29, 2024 |
Richard Newitter Truist Securities | Hold | $46 | Maintains | Oct 14, 2024 |
Mike Matson Needham | Hold | Reiterates | Oct 9, 2024 | |
Mathew Blackman Stifel | Hold | $50 | Initiates | Sep 17, 2024 |
Mike Kratky Leerink Partners | Market Perform | $47 | Initiates | Sep 3, 2024 |
Adam Maeder Piper Sandler | Neutral | $50 | Maintains | Aug 26, 2024 |
Pito Chickering Deutsche Bank | Buy | $68 | Initiates | Aug 9, 2024 |
William Plovanic Canaccord Genuity | Buy | $71 | Maintains | Jul 31, 2024 |
Mike Matson Needham | Hold | Reiterates | Jul 31, 2024 | |
David Rescott Baird | Outperform | $63 | Maintains | Jul 31, 2024 |
Richard Newitter Truist Securities | Hold | $55 | Reiterates | Jul 31, 2024 |
Larry Biegelsen Wells Fargo | Overweight | $65 | Maintains | Jul 31, 2024 |
Margaret Andrew William Blair | Outperform | Initiates | Jul 25, 2024 | |
Mike Matson Needham | Hold | Downgrade | Jul 18, 2024 | |
Richard Newitter Truist Securities | Hold | $60 | Maintains | Jul 16, 2024 |
When did it IPO
2020
Staff Count
1,300
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Andrew J. Hykes
Market Cap
$2.90B
In 2023, NARI generated $493.6M in revenue, which was a increase of 28.73% from the previous year. This can be seen as a signal that NARI's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Inari Medical, Inc. (NASDAQ:NARI) will hold its Q3 2024 earnings conference call on October 28, 2024, at 4:30 PM ET, featuring key company executives and analysts from various firms.
Why It Matters - The earnings call indicates Inari Medical's financial performance and strategic direction, impacting stock valuation and investor sentiment in the medical device sector.
Summary - Inari Medical, Inc. (NASDAQ: NARI) reported its Q3 2024 financial results, continuing its focus on treating patients with venous and other diseases.
Why It Matters - Inari Medical's Q3 financial results provide insights into its performance and growth potential, impacting stock valuation and investor sentiment in the medical device sector.
Summary - Inari Medical, Inc. (NARI) reported a quarterly loss of $0.13 per share, slightly worse than the expected loss of $0.12, compared to earnings of $0.05 per share in the same quarter last year.
Why It Matters - Inari Medical's larger-than-expected quarterly loss signals potential operational challenges, impacting investor confidence and stock performance. Year-over-year earnings decline raises further concerns.
Summary - NARI's Q3 results show increased revenues but poor profitability, with contracting gross margins and ongoing operating losses.
Why It Matters - NARI's revenue growth contrasts with declining gross margins and ongoing losses, signaling potential operational challenges and impacting future profitability and investor confidence.
Summary - The company achieved a primary endpoint win, supported by strong clinical outcomes and effective use of hospital resources.
Why It Matters - Positive clinical outcomes and efficient resource use can enhance a company's credibility and market position, potentially leading to increased revenue and stock performance.
Summary - Inari Medical (NARI) is expected to lack the necessary factors for a potential earnings beat in its upcoming report, signaling caution for investors.
Why It Matters - Inari Medical's lack of key ingredients for an earnings beat suggests potential underperformance, impacting stock price and investor sentiment.